FDA Draft Attempts To Fill Gap From Expired Off-Label Distribution Reg
This article was originally published in The Gray Sheet
Executive Summary
A draft 1guidance spelling out the circumstances under which manufacturers can distribute journal article reprints describing off-label uses of their products may offer a little more leeway, but it is not expected to have a major impact on oversight of marketing practices, industry lawyers say
You may also be interested in...
Extra Caution Needed In Uncertain Period For Off-Label Info Distribution
Until FDA finalizes guidance on what practices are acceptable in distributing journal articles that describe off-label product indications, companies should watch their step in avoiding investigations that could lead to fines, criminal prosecution or exclusion from federal reimbursement programs, attorneys say
Extra Caution Needed In Uncertain Period For Off-Label Info Distribution
Until FDA finalizes guidance on what practices are acceptable in distributing journal articles that describe off-label product indications, companies should watch their step in avoiding investigations that could lead to fines, criminal prosecution or exclusion from federal reimbursement programs, attorneys say
Waxman Asks FDA Not To Issue Guidance On Off-Label Promotion
Rep. Henry Waxman, chair of the House Committee on Oversight and Government Reform, is urging FDA not to go forward with a guidance that he says would allow companies to use journal articles to promote off-label uses of devices and drugs